Duloxetine Hydrochloride
Product Images NDC 64725-1100

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 64725-1100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (64725 1100)

Label for Duloxetine hydrochloride delayed-release capsules, 30 mg strength, in a package of 30 capsules. The label indicates prescription use only, manufacturer Torrent, and repackaged by TYA Pharmaceuticals in Tallahassee, FL. It includes a barcode and advises to see the package insert for dosing information.*

FDA Label Image

Structure (Duloxetinedrcapsules Figure 01)

Chemical structure diagram of Duloxetine hydrochloride showing its molecular framework, including aromatic rings and functional groups.*

FDA Label Image

1 (Duloxetinedrcapsules Figure 02)

A line graph showing the percentage of patients achieving various levels of pain relief from baseline as measured by 24-hour average pain severity in a study labeled DPnP-1 for Duloxetine hydrochloride. The graph compares four groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and placebo. The vertical axis represents the percentage of patients improved, decreasing from about 70% to 0%, and the horizontal axis indicates percent improvement in pain from baseline, ranging from 0 to 100%.*

FDA Label Image

2 (Duloxetinedrcapsules Figure 03)

A line graph showing the percentage of patients achieving various levels of pain relief based on percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo, illustrating higher percentages of patients improved with Duloxetine doses compared to placebo.*

FDA Label Image

Graph (Duloxetinedrcapsules Figure 04)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo groups. The vertical axis shows the percentage of patients improved from 0 to 100%, and the horizontal axis shows percent improvement in pain from 0 to 100%. Two lines are plotted: one with diamonds for Duloxetine and another with crosses for placebo, illustrating patient response levels.*

FDA Label Image

Figure 6 (Duloxetinedrcapsules Figure 05)

A line graph titled 'Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – CLBP-3' comparing placebo and Duloxetine 60 mg once daily. The x-axis represents percent improvement in pain from baseline (BOCF) from >0 to 100, and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Two line plots depict that a higher percentage of patients improved with Duloxetine 60 mg daily compared to placebo across most levels of pain improvement.*

FDA Label Image

Graph (Duloxetinedrcapsules Figure 06)

Line graph titled 'Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity – OA-1'. It shows two plotted lines: one for placebo marked with 'x' symbols, and one for Duloxetine 60/120 mg once daily marked with diamond symbols. The x-axis represents percent improvement in pain from baseline (BOCF), ranging from >0 to 100, and the y-axis represents the percentage of patients improved, ranging from 0 to 100 percent. The Duloxetine line generally shows higher percentages of patient improvement compared to placebo across the percent improvement scale.*

FDA Label Image

Logo (Duloxetinedrcapsules Figure 07)

FDA Label Image

Logo (Duloxetinedrcapsules Figure 08)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.